Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Durvalumab increases overall survival in stage III non-small-cell lung cancer

For the first time, immunotherapy has been shown to improve overall survival in patients with stage III non-small-cell lung cancer.

Immunoglobulin drug 3d structure


Durvalumab, an engineered human IgG1 monoclonal antibody that blocks the effect of programmed death ligand 1, has been found to prolong survival in people with stage III non-small-cell lung cancer by over 30% compared with placebo

The immune checkpoint inhibitor durvalumab significantly improves survival in people with stage III non-small-cell lung cancer (NSCLC), interim trial results published in The New England Journal of Medicine (25 September 2018) have shown[1].

The study involved patients with stage III unresectable NSCLC whose disease had not progressed following chemoradiotherapy. Overall, 473 patients received durvalumab and 236 patients received placebo by infusion every 2 weeks for up to 12 months.

The results showed that durvalumab significantly increased the overall survival rate at 24 months to 66.3%, compared with 55.6% in the placebo group. Durvalumab was also found to prolong survival by over 30% when compared with placebo.

An earlier analysis in the phase III trial had indicated that the immunotherapy increased progression-free survival in this group of patients and the treatment was consequently authorised by the European Medicines Agency in September 2018.

The researchers noted that this was the first time an immunotherapy had been shown to improve survival in patients with stage III NSCLC.

“With the between-group difference in median progression-free survival remaining more than 11 months, the results of the analysis of overall survival indicate that the progression-free survival benefit has translated to a significant prolongation in overall survival,” they said. 

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205750

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Immunoglobulin drug 3d structure

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.